ArticlePharmacoEconomics2020
Why it's Time to Abandon the ICER.
Article in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Negative pressure wound therapy for surgical wounds healing by secondary intention is not cost-effective.The British journal of surgery · 2025Pooled it
- Cost Effectiveness of Deep Brain Stimulation for Parkinson's Disease: A Systematic Review.Applied health economics and health policy · 2024Pooled it
- Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.The Australian and New Zealand journal of psychiatry · 2024Pooled it
- Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies.Frontiers in pharmacology · 2022Pooled it
- Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.PloS one · 2022Pooled it
- Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury.International journal of technology assessment in health care · 2025Trial
- Cost-effectiveness of Transcendental Meditation (TM) for treating Post-Traumatic Stress Disorder (PTSD).PloS one · 2025Trial
- Cost-utility and cost consequence of a telehealth intervention targeting improvement in addictive eating for Australian adults (the TRACE program).Journal of public health (Oxford, England) · 2024Trial
- Arthroscopic Partial Meniscectomy for a Degenerative Meniscus Tear Is Not Cost Effective Compared With Placebo Surgery: An Economic Evaluation Based on the FIDELITY Trial Data.Clinical orthopaedics and related research · 2024Trial
- Cost-utility of a multicomponent intervention for fibromyalgia versus usual care: a pragmatic randomised controlled trial.Journal of rehabilitation medicine · 2023Trial
- Cost-utility analysis and net monetary benefit of Platelet Rich Plasma (PRP), intra-articular injections in compared to Plasma Rich in Growth Factors (PRGF), Hyaluronic Acid (HA) and ozone in knee osteoarthritis in Iran.BMC musculoskeletal disorders · 2023Trial
- Comparing User-Written Codes for Performing Economic Evaluations in Stata.PharmacoEconomics · 2026Review
- A Practical Framework for Understanding Cost-Effectiveness and Decision Risk in Health Benefits Package Design.Applied health economics and health policy · 2026Article
- Cost-utility analysis of deep learning-based opportunistic osteoporosis screening using chest radiographs: implications of diagnostic thresholds and confirmatory testing.Archives of osteoporosis · 2026Article
- Cost-Effectiveness of Annual Atrial Fibrillation Screening Compared with Current Opportunistic Screening in Australian Primary Care: A Model-Based Economic Evaluation.Applied health economics and health policy · 2026Article
- Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan.Dermatology and therapy · 2026Article
- A Threshold Inequality Aversion Parameter Approach to Interpret Distributional Cost-Effectiveness Analysis Results.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026Article
- Approaches to modeling treatment sequencing in practice: a thematic review of prior NICE appraisals.International journal of technology assessment in health care · 2025Review
- Protocol for the economic evaluation of the "Healthy for Two/Healthy for You" pragmatic lifestyle intervention in prenatal care to reduce gestational weight gain and gestational diabetes mellitus.Contemporary clinical trials · 2025Article
- Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making.Applied health economics and health policy · 2025Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32390066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.